Cosmos Health makes first move into animal health with C-Scrub
Bottom line
Cosmos Health says it plans to enter animal health with a veterinary version of C-Scrub Wash 4%, a chlorhexidine digluconate 4% antimicrobial wash already sold for human use, starting in the UK. The company said the move follows independent testing showing the product met European veterinary disinfectant standards EN 1656:2019 for bactericidal activity and EN 1657:2024 for yeasticidal activity under defined lab conditions, including a 10-minute contact time. Cosmos said this would be its first move into the animal health market, with manufacturing through its subsidiary Cana Laboratories and broader international expansion planned after the UK launch. (nasdaq.com)
Why it matters: For veterinary professionals, this is less about a breakthrough active ingredient than a new commercial entrant built around a familiar one. Chlorhexidine is already widely used in veterinary hygiene and skin-cleansing protocols, and infection prevention remains a growing focus in practice biosecurity. The practical question will be whether Cosmos can translate bench-standard efficacy into a clearly positioned veterinary product that fits clinic workflows, purchasing preferences, and local regulatory requirements in the UK and beyond. In Great Britain, veterinary hygiene biocides sit under the GB Biocidal Products Regulation, while some animal-use products can instead fall under veterinary medicines rules depending on claims and intended use. (merckvetmanual.com)
What to watch: Watch for specifics on UK commercialization, including product claims, regulatory pathway, channel strategy, and whether Cosmos seeks broader approvals or Defra-related positioning for particular veterinary uses. (gov.uk)
Cosmos Health is making its first push into animal health with a planned veterinary formulation of C-Scrub Wash 4%, extending a chlorhexidine-based antimicrobial wash brand it already markets in human healthcare. The company announced June 1, 2026, that it will launch first in the UK after reporting successful independent testing against European veterinary disinfectant standards EN 1656:2019 and EN 1657:2024. (nasdaq.com)
The move builds on a broader expansion strategy around the C-Scrub brand. Earlier in 2026, Cosmos disclosed successful EN 12791 testing for surgical hand disinfection, and in March said C-Scrub had expanded into UK retail through Superdrug. That history matters because the veterinary launch appears to be a brand extension rather than a brand-new molecule or platform: Cosmos is leveraging an existing chlorhexidine product, existing manufacturing capacity at Cana Laboratories, and an existing UK commercial footprint. (finance.yahoo.com)
According to the company, C-Scrub Wash 4% contains chlorhexidine digluconate 4% w/v and was tested by QACS, an EU-based laboratory accredited to EN ISO/IEC 17025:2017. Cosmos said the product met the EN 1656 bactericidal threshold of at least a 5-log reduction against four required reference organisms, including Pseudomonas aeruginosa, Staphylococcus aureus, Proteus hauseri, and Enterococcus hirae, at both 80% and 50% concentrations. It also said the wash met the EN 1657 yeasticidal threshold of at least a 4-log reduction against Candida albicans. Testing was conducted in May 2026 under clean conditions with 3 g/L bovine albumin at 20°C and a 10-minute contact time. EN 1656 and EN 1657 are standardized veterinary-area suspension tests intended to establish baseline bactericidal and yeasticidal efficacy under controlled conditions, not real-world field performance on every surface or use case. (nasdaq.com)
Cosmos framed the opportunity around market growth, citing animal health as a roughly $68.7 billion global market in 2025. That headline number helps explain investor interest, but for veterinary teams the more relevant point is where the product may fit operationally. The company said intended animal-health uses include breeding, husbandry, veterinary care facilities, transport environments, and related professional settings. In other words, it appears aimed at hygiene and disinfection workflows across veterinary and animal-care settings, rather than at a therapeutic veterinary medicine. (nasdaq.com)
External commentary on the specific Cosmos launch appears limited so far, but the broader infection-control context is clear. Recent veterinary biosecurity literature describes healthcare-associated infections in veterinary settings as a persistent challenge with animal health, cost, and zoonotic implications. Reference materials for veterinarians also show chlorhexidine remains a common antiseptic and skin-cleanser active, while noting that product performance depends on formulation, application, and contamination control. Merck Veterinary Manual, for example, notes that 4% chlorhexidine emulsions are used as skin cleansers, but also cautions that contaminated chlorhexidine products have been linked to outbreaks. A UK veterinary industry commentary likewise recently described 4% chlorhexidine as a core tool in hygiene practice because of its residual activity. (sciencedirect.com)
Why it matters: For veterinary professionals, this announcement is best read as a market-entry signal, not a practice-changing evidence event. The standards Cosmos cites are meaningful because they are recognized efficacy benchmarks for veterinary disinfectants and antiseptics, and passing them may support future product claims and commercialization. But a successful suspension test is only one piece of the purchasing and clinical-use picture. Veterinary clinics, hospitals, shelters, and livestock operations will still want clarity on label claims, contact times, compatibility with workflows and surfaces, safety profile, cost, and how the product is positioned relative to established disinfectants and skin-prep options already in use. (standards.iteh.ai)
Regulatory framing will also matter. In Great Britain, biocidal products are regulated by the Health and Safety Executive under the GB Biocidal Products Regulation, while some animal-use products can instead be regulated as veterinary medicines depending on intended purpose and claims. UK government guidance also notes there is generally no legal requirement for a routine veterinary practice, kennel, or cattery to use a Defra-approved disinfectant unless there is an outbreak of a notifiable animal disease. That means Cosmos's commercial success may depend less on the headline test result and more on how precisely it navigates regulatory classification, labeling, and channel access in the UK market it has chosen as its first launch pad. (hse.gov.uk)
What to watch: The next signals to watch are a formal UK product launch date, the exact regulatory route and claims package, whether Cosmos pursues veterinary clinic distribution versus broader animal-care channels, and whether it publishes more detailed efficacy or use-case data beyond the initial EN 1656 and EN 1657 results. (nasdaq.com)